King B, Ehst B, Foley P, Reygagne P, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients with alopecia areata: efficacy and safety results of a phase II, multicentre, randomized, double-blinded, placebo-controlled trial. Br J Dermatol 2026;195:211-221.
PMID: 41905775